 David Moreno
Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Waldenstrom Macroglobulinemia | 4 | 2023 | 10 | 2.930 |
Why?
| | Lymphoma, B-Cell | 3 | 2023 | 86 | 2.530 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 3 | 2023 | 3 | 2.080 |
Why?
| | Saccharomyces cerevisiae Proteins | 9 | 2023 | 350 | 1.990 |
Why?
| | Saccharomyces cerevisiae | 10 | 2023 | 509 | 1.900 |
Why?
| | Multiple Myeloma | 5 | 2022 | 101 | 1.570 |
Why?
| | Proteostasis | 2 | 2020 | 19 | 1.500 |
Why?
| | Molecular Chaperones | 3 | 2019 | 176 | 1.440 |
Why?
| | Cellular Senescence | 2 | 2020 | 151 | 1.360 |
Why?
| | Plasmacytoma | 2 | 2022 | 14 | 1.110 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2022 | 29 | 0.880 |
Why?
| | Calcaneus | 1 | 2022 | 58 | 0.840 |
Why?
| | Pharmaceutical Preparations | 2 | 2020 | 170 | 0.830 |
Why?
| | Myeloid Differentiation Factor 88 | 4 | 2023 | 96 | 0.830 |
Why?
| | Sarcoma, Ewing | 1 | 2022 | 71 | 0.820 |
Why?
| | Galactokinase | 1 | 2020 | 5 | 0.800 |
Why?
| | Automation | 1 | 2020 | 79 | 0.770 |
Why?
| | Epistasis, Genetic | 1 | 2020 | 73 | 0.770 |
Why?
| | Cell Enlargement | 2 | 2019 | 4 | 0.760 |
Why?
| | High-Throughput Screening Assays | 2 | 2020 | 122 | 0.750 |
Why?
| | Bone Neoplasms | 1 | 2022 | 207 | 0.740 |
Why?
| | Graft vs Host Disease | 2 | 2019 | 223 | 0.730 |
Why?
| | G1 Phase Cell Cycle Checkpoints | 1 | 2019 | 8 | 0.720 |
Why?
| | Cell Cycle Checkpoints | 1 | 2019 | 91 | 0.710 |
Why?
| | Cell Size | 1 | 2019 | 86 | 0.710 |
Why?
| | Intravital Microscopy | 1 | 2019 | 17 | 0.700 |
Why?
| | Time-Lapse Imaging | 1 | 2019 | 21 | 0.690 |
Why?
| | Histone Deacetylases | 1 | 2020 | 204 | 0.690 |
Why?
| | Heat-Shock Response | 1 | 2019 | 58 | 0.690 |
Why?
| | DNA Replication | 1 | 2020 | 220 | 0.690 |
Why?
| | Chromatin | 1 | 2020 | 451 | 0.600 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2020 | 542 | 0.590 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2019 | 727 | 0.500 |
Why?
| | Cyclins | 4 | 2021 | 84 | 0.440 |
Why?
| | Smoldering Multiple Myeloma | 2 | 2021 | 2 | 0.430 |
Why?
| | Immunoglobulin M | 3 | 2022 | 249 | 0.410 |
Why?
| | Receptors, CXCR4 | 2 | 2022 | 83 | 0.400 |
Why?
| | CDC28 Protein Kinase, S cerevisiae | 2 | 2021 | 7 | 0.390 |
Why?
| | Mutation | 4 | 2023 | 3516 | 0.340 |
Why?
| | HSP40 Heat-Shock Proteins | 2 | 2019 | 21 | 0.330 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2022 | 693 | 0.300 |
Why?
| | Protein Biosynthesis | 4 | 2022 | 415 | 0.300 |
Why?
| | Gene Expression Regulation, Fungal | 3 | 2023 | 67 | 0.290 |
Why?
| | Disease-Free Survival | 2 | 2022 | 678 | 0.230 |
Why?
| | Prognosis | 2 | 2022 | 3601 | 0.220 |
Why?
| | Immunoglobulin Light-chain Amyloidosis | 1 | 2021 | 3 | 0.220 |
Why?
| | Molecular Dynamics Simulation | 2 | 2020 | 214 | 0.210 |
Why?
| | Peptide Elongation Factor 1 | 1 | 2021 | 9 | 0.210 |
Why?
| | Immunoglobulin Light Chains | 1 | 2021 | 35 | 0.210 |
Why?
| | Allografts | 1 | 2022 | 129 | 0.210 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2021 | 67 | 0.210 |
Why?
| | Dendritic Spines | 1 | 2021 | 50 | 0.200 |
Why?
| | Humans | 18 | 2023 | 121723 | 0.200 |
Why?
| | Genes, Regulator | 1 | 2020 | 34 | 0.200 |
Why?
| | Cell Cycle | 2 | 2021 | 577 | 0.190 |
Why?
| | Hydroxamic Acids | 1 | 2020 | 83 | 0.190 |
Why?
| | Niacinamide | 1 | 2020 | 71 | 0.190 |
Why?
| | Cytoplasmic Granules | 1 | 2021 | 103 | 0.190 |
Why?
| | Bone Marrow | 1 | 2021 | 259 | 0.190 |
Why?
| | Calibration | 1 | 2020 | 140 | 0.190 |
Why?
| | Feedback, Physiological | 1 | 2020 | 77 | 0.190 |
Why?
| | Epigenomics | 1 | 2020 | 109 | 0.190 |
Why?
| | Small Molecule Libraries | 1 | 2020 | 83 | 0.180 |
Why?
| | Immunotherapy, Adoptive | 1 | 2021 | 189 | 0.180 |
Why?
| | Photopheresis | 1 | 2019 | 9 | 0.180 |
Why?
| | S Phase Cell Cycle Checkpoints | 1 | 2019 | 5 | 0.180 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 883 | 0.180 |
Why?
| | Polymerase Chain Reaction | 1 | 2022 | 1033 | 0.180 |
Why?
| | Drug Discovery | 1 | 2020 | 127 | 0.180 |
Why?
| | Cell Nucleolus | 1 | 2019 | 18 | 0.180 |
Why?
| | Luminescent Agents | 1 | 2019 | 6 | 0.180 |
Why?
| | Actins | 1 | 2021 | 378 | 0.180 |
Why?
| | Spatio-Temporal Analysis | 1 | 2019 | 29 | 0.170 |
Why?
| | Acute Disease | 2 | 2019 | 986 | 0.170 |
Why?
| | Cyclin G1 | 1 | 2018 | 1 | 0.170 |
Why?
| | Lymphoma | 1 | 2020 | 185 | 0.170 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 255 | 0.170 |
Why?
| | Cell Growth Processes | 1 | 2018 | 55 | 0.170 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2019 | 77 | 0.170 |
Why?
| | Centromere | 1 | 2018 | 43 | 0.170 |
Why?
| | Spectrometry, Fluorescence | 1 | 2019 | 172 | 0.170 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2019 | 116 | 0.160 |
Why?
| | Genomics | 1 | 2023 | 687 | 0.160 |
Why?
| | Adenosine Triphosphatases | 1 | 2019 | 166 | 0.160 |
Why?
| | Luminescent Proteins | 1 | 2019 | 170 | 0.160 |
Why?
| | Models, Molecular | 2 | 2020 | 1459 | 0.160 |
Why?
| | Stress, Physiological | 1 | 2021 | 431 | 0.160 |
Why?
| | Pleural Effusion | 1 | 2017 | 54 | 0.150 |
Why?
| | Models, Biological | 2 | 2021 | 1771 | 0.150 |
Why?
| | Biological Evolution | 1 | 2020 | 460 | 0.150 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 548 | 0.140 |
Why?
| | Skin Diseases | 1 | 2018 | 164 | 0.140 |
Why?
| | Chronic Disease | 2 | 2019 | 1655 | 0.140 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1288 | 0.140 |
Why?
| | Recombinant Proteins | 1 | 2019 | 1332 | 0.130 |
Why?
| | Dexamethasone | 1 | 2017 | 312 | 0.130 |
Why?
| | Endoplasmic Reticulum | 1 | 2017 | 242 | 0.130 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1415 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1438 | 0.120 |
Why?
| | Glucocorticoids | 1 | 2017 | 553 | 0.110 |
Why?
| | Incidence | 1 | 2018 | 2519 | 0.110 |
Why?
| | Signal Transduction | 2 | 2022 | 4810 | 0.100 |
Why?
| | Transplantation, Autologous | 2 | 2022 | 197 | 0.100 |
Why?
| | T-Lymphocytes | 1 | 2018 | 1795 | 0.100 |
Why?
| | Molecular Conformation | 2 | 2020 | 149 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 2016 | 0.080 |
Why?
| | Male | 6 | 2022 | 60425 | 0.070 |
Why?
| | Middle Aged | 5 | 2021 | 28928 | 0.060 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2023 | 46 | 0.060 |
Why?
| | Adolescent | 1 | 2022 | 19118 | 0.060 |
Why?
| | Child | 1 | 2022 | 19271 | 0.060 |
Why?
| | Biological Transport | 1 | 2023 | 390 | 0.060 |
Why?
| | Aged | 4 | 2021 | 20688 | 0.050 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2022 | 141 | 0.050 |
Why?
| | Iron | 1 | 2023 | 243 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2021 | 204 | 0.050 |
Why?
| | Intrinsically Disordered Proteins | 1 | 2021 | 16 | 0.050 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 80 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2021 | 4880 | 0.050 |
Why?
| | Trans-Activators | 1 | 2023 | 395 | 0.050 |
Why?
| | History, 21st Century | 1 | 2021 | 186 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2021 | 264 | 0.050 |
Why?
| | Actin Cytoskeleton | 1 | 2021 | 88 | 0.050 |
Why?
| | Databases, Protein | 1 | 2020 | 69 | 0.050 |
Why?
| | History, 20th Century | 1 | 2021 | 298 | 0.050 |
Why?
| | Immunoglobulin A | 1 | 2021 | 176 | 0.050 |
Why?
| | Molecular Weight | 1 | 2020 | 351 | 0.050 |
Why?
| | Carcinogenesis | 1 | 2021 | 182 | 0.050 |
Why?
| | Quantum Theory | 1 | 2020 | 99 | 0.050 |
Why?
| | Aged, 80 and over | 2 | 2021 | 6964 | 0.050 |
Why?
| | Blood Viscosity | 1 | 2019 | 23 | 0.050 |
Why?
| | Proteasome Inhibitors | 1 | 2019 | 47 | 0.050 |
Why?
| | Female | 6 | 2021 | 63833 | 0.040 |
Why?
| | Mortality | 1 | 2021 | 323 | 0.040 |
Why?
| | Neuronal Plasticity | 1 | 2021 | 229 | 0.040 |
Why?
| | Antibiotic Prophylaxis | 1 | 2020 | 100 | 0.040 |
Why?
| | HeLa Cells | 1 | 2021 | 612 | 0.040 |
Why?
| | Anti-Bacterial Agents | 2 | 2020 | 1491 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2022 | 393 | 0.040 |
Why?
| | Ligands | 1 | 2020 | 556 | 0.040 |
Why?
| | Rituximab | 1 | 2019 | 158 | 0.040 |
Why?
| | Saccharomycetales | 1 | 2018 | 15 | 0.040 |
Why?
| | G1 Phase | 1 | 2018 | 72 | 0.040 |
Why?
| | Survival Analysis | 1 | 2021 | 1356 | 0.040 |
Why?
| | Piperidines | 1 | 2019 | 167 | 0.040 |
Why?
| | Proteolysis | 1 | 2018 | 142 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2021 | 1237 | 0.040 |
Why?
| | Adenine | 1 | 2019 | 227 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2021 | 792 | 0.040 |
Why?
| | Disease Management | 1 | 2021 | 608 | 0.040 |
Why?
| | Computational Biology | 1 | 2021 | 661 | 0.040 |
Why?
| | Cell Division | 1 | 2018 | 786 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2021 | 1176 | 0.040 |
Why?
| | Pyrimidines | 1 | 2019 | 393 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2018 | 450 | 0.040 |
Why?
| | Pyrazoles | 1 | 2019 | 399 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2021 | 1200 | 0.040 |
Why?
| | Community-Acquired Infections | 1 | 2017 | 148 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2021 | 1066 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1628 | 0.030 |
Why?
| | Protein Binding | 1 | 2021 | 2017 | 0.030 |
Why?
| | Databases, Factual | 1 | 2020 | 1285 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2017 | 362 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1828 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 576 | 0.030 |
Why?
| | Proteins | 1 | 2020 | 954 | 0.030 |
Why?
| | Disease Progression | 1 | 2021 | 2581 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 1003 | 0.030 |
Why?
| | Gene Expression | 1 | 2019 | 1530 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2018 | 611 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1190 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 3079 | 0.030 |
Why?
| | Neurons | 1 | 2021 | 1370 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2021 | 2746 | 0.030 |
Why?
| | Recovery of Function | 1 | 2017 | 611 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2017 | 1719 | 0.030 |
Why?
| | Pneumonia | 1 | 2017 | 597 | 0.030 |
Why?
| | Cohort Studies | 1 | 2021 | 5296 | 0.030 |
Why?
| | Prospective Studies | 1 | 2021 | 6625 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 6885 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2019 | 9648 | 0.020 |
Why?
| | Child, Preschool | 1 | 2017 | 9771 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2019 | 13053 | 0.010 |
Why?
| | Adult | 1 | 2021 | 32638 | 0.010 |
Why?
|
|
Moreno's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|